Bone matrix quality after sclerostin antibody treatment

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1597-1607

  Ross, Ryan D ^a   Edwards, Lindsey H ^a   Acerbo, Alvin S ^b,c   Ominsky, Michael S ^d   Virdi, Amarjit S ^a   Sena, Kotaro ^a   Miller, Lisa M ^b,c   Sumner, D Rick ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b St Francis Hospital The Heart Center   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d AMGEN INC   (United States)

Author keywords

BACKSCATTER SCANNING ELECTRON MICROSCOPY; BONE; BONE MINERAL DENSITY DISTRIBUTION; FOURIER TRANSFORM INFRARED IMAGING; MINERALIZATION; MINERALIZATION KINETICS; SCLEROSTIN ANTIBODY

Indexed keywords

CARBONIC ACID; COLLAGEN; PROTEIN ANTIBODY; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MATRIX; BONE MATRIX QUALITY; BONE MINERALIZATION; CONTROLLED STUDY; CORTICAL BONE; CROSS LINKING; INFRARED SPECTROSCOPY; MALE; MICRO-COMPUTED TOMOGRAPHY; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; PRIMATE MODEL; RAT; SCANNING ELECTRON MICROSCOPY; TRABECULAR BONE; ANIMAL; ANIMAL MODEL; ANTIBODY SPECIFICITY; DIAPHYSIS; DRUG EFFECTS; FEMUR; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; MACACA FASCICULARIS; METABOLISM; RADIOGRAPHY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES; BONE DENSITY; BONE MATRIX; DIAPHYSES; FEMUR; GLYCOPROTEINS; MACACA FASCICULARIS; MALE; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; ORGAN SPECIFICITY; RATS, SPRAGUE-DAWLEY; X-RAY MICROTOMOGRAPHY;

EID: 84898764426     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2188     Document Type: Article

References (68)

1. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009; 24: 1662-71.
2. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009; 24: 1651-61.
3. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P., Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010; 25: 2412-8.
4. Tian X, Jee WS, Li X, Paszty C., Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011; 48: 197-201.
5. Ominsky MS, Li C, Li X., etal, Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res. 2011; 26: 1012-21.
6. Virdi AS, Liu M, Sena K, et al. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am. 2012; 94: 1670-80.
7. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578-88.
8. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS., Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010; 47: 529-33.
9. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25: 948-59.
10. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25: 2371-80.
11. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011; 152: 3312-22.
12. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
13. Seeman E, Delmas PD., Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354: 2250-61.
14. Turner CH., Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 2002; 13: 97-104.
15. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation but not a classical BMP antagonist. J Exp Med. 2004; 199: 805-14.
16. van Bezooijen RL, Papapoulos SE, Lowik CW., Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest. 2005; 28: 15-7.
17. Baron R, Rawadi G., Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635-43.
18. Piters E, Boudin E, Van Hul W., Wnt signaling: a win for bone. Arch Biochem Biophys. 2008; 473: 112-6.
19. van Bezooijen RL, Bronckers AL, Gortzak RA, et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88: 569-74.
20. Galli C, Passeri G, Macaluso GM., Osteocytes and WNT: the mechanical control of bone formation. J Dent Res. 2010; 89: 331-43.
21. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW., SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16: 319-27.
22. Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P., Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res. 2010; 25: 2297-303.
23. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88: 1150-6.
24. Kneissel M, Boyde A, Gasser JA., Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PT H(1-34). Bone. 2001; 28: 237-50.
25. Roschger P, Dempster DW, Zhou H, et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res. 2007; 22: 717-23.
26. Broderick E, Infanger S, Turner TM, Sumner DR, Depressed bone mineralization following high dose TGF-beta1 application in an orthopedic implant model. Calcif Tissue Int. 2005; 76: 379-84.
27. Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO., Enhancement of bone ingrowth by transforming growth factor beta. J Bone Joint Surg. 1995; 77-A: 1135-47.
28. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987; 2: 595-610.
29. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
30. Roschger P, Fratzl P, Eschberger J, Klaushofer K., Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies [see comments]. Bone. 1998; 23: 319-26.
31. Boyce TM, Bloebaum RD, Bachus KN, Skedros JG., Reproducible methods for calibrating the backscattered electron signal for quantitative assessment of mineral content in bone. Scanning Microsc. 1990; 4: 591-600.
32. Roschger P, Gupta HS, Berzlanovich A, et al. Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32: 316-23.
33. Kiratli BJ, Heiner JP, McBeath AA, Wilson MA., Determination of bone mineral density by dual x-ray absorptiometry in patients with uncemented total hip arthroplasty. J Orthop Res. 1992; 10: 836-44.
34. Fuchs RK, Faillace ME, Allen MR, Phipps RJ, Miller LM, Burr DB., Bisphosphonates do not alter the rate of secondary mineralization. Bone. 2011; 49: 701-5.
35. Fuchs RK, Allen MR, Ruppel ME, et al. In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. Matrix Biol. 2008; 27: 34-41.
36. Miller LM, Little W, Schirmer A, Sheik F, Busa B, Judex S., Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res. 2007; 22: 1037-45.
37. Acerbo AS, Carr GL, Judex S, Miller LM., Imaging the material properties of bone specimens using reflection-based infrared microspectroscopy. Anal Chem. 2012; 84: 3607-13.
38. Rho JY, Mishra SR, Chung K, Bai J, Pharr GM., Relationship between ultrastructure and the nanoindentation properties of intramuscular herring bones. Ann Biomed Eng. 2001; 29: 1082-8.
39. Burket J, Gourion-Arsiquaud S, Havill LM, Baker SP, Boskey AL, van der Meulen MC., Microstructure and nanomechanical properties in osteons relate to tissue and animal age. J Biomech. 2011; 44: 277-84.
40. Mulder L, Koolstra JH, den Toonder JM, van Eijden TM., Relationship between tissue stiffness and degree of mineralization of developing trabecular bone. J Biomed Mater Res A. 2007; 84: 508-15.
41. Mulder L, Koolstra JH, den Toonder JM, van Eijden TM., Intratrabecular distribution of tissue stiffness and mineralization in developing trabecular bone. Bone. 2007; 41: 256-65.
42. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM., Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013; 28: 73-80.
43. Donnelly E, Boskey AL, Baker SP, van der Meulen MC., Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. J Biomed Mater Res A. 2010; 92: 1048-56.
44. Marotti G, Favia A, Zallone AZ., Quantitative analysis on the rate of secondary bone mineralization. Calcif Tissue Res. 1972; 10: 67-81.
45. Landis WJ, Silver FH., The structure and function of normally mineralizing avian tendons. Comp Biochem Physiol A Mol Integr Physiol. 2002; 133: 1135-57.
46. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB., Aging of microstructural compartments in human compact bone. J Bone Miner Res. 2003; 18: 1012-9.
47. Boivin G, Meunier PJ., Methodological considerations in measurement of bone mineral content. Osteoporos Int. 2003; 14 (Suppl 5): S22-7.
48. Fratzl P, Gupta HS, Paschalis EP, Roschger P., Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem. 2004; 4: 2115-23.
49. Busa B, Miller LM, Rubin CT, Qin YX, Judex S., Rapid establishment of chemical and mechanical properties during lamellar bone formation. Calcif Tissue Int. 2005; 77: 386-94.
50. Ruffoni D, Fratzl P, Roschger P, Klaushofer K, Weinkamer R., The bone mineralization density distribution as a fingerprint of the mineralization process. Bone. 2007; 40: 1308-19.
51. Roschger P, Paschalis EP, Fratzl P, Klaushofer K., Bone mineralization density distribution in health and disease. Bone. 2008; 42: 456-66.
52. Boivin G, Meunier PJ., Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res. 2002; 43: 535-7.
53. Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. 2003; 33: 960-9.
54. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB., Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15: 613-20.
55. Allen MR, Burr DB., Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy-Osteovision. 2007; 4: 49-60.
56. Roschger P, Fratzl P, Klaushofer K, Rodan G., Mineralization of cancellous bone after alendronate and sodium flouride treatment: a quantitative backscattered electron imaging study of minipig ribs. Bone. 1997; 20: 393-7.
57. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K., Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001; 29: 185-91.
58. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, et al. Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effects of etidronate treatment. J Bone Miner Res. 2002; 17: 1372-82.
59. Zoehrer R, Roschger P, Paschalis EP, et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. 2006; 21: 1106-12.
60. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K., Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int. 2007; 81: 73-80.
61. Wergedal JE, Baylink DJ., Electron microprobe measurements of bone mineralization rate in vivo. Am J Physiol. 1974; 226: 345-52.
62. Baylink D, Stauffer M, Wergedal J, Rich C., Formation, mineralization, and resorption of bone in vitamin D-deficient rats. J Clin Invest. 1970; 49: 1122-34.
63. Amprino R, Engstrom A., Studies on x ray absorption and diffraction of bone tissue. Acta Anat (Basel). 1952; 15: 1-22.
64. Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011; 26: 1425-36.
65. Hasegawa T, Amizuka N, Yamada T, et al. Sclerostin is differently immunolocalized in metaphyseal trabecules and cortical bones of mouse tibiae. Biomed Res. 2013; 34: 153-9.
66. Misof BM, Roschger P, Gabriel D, et al. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res. 2013; 28: 442-8.
67. Liu S, Virdi AS, Sena K, Sumner DR, Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model. Arthritis Rheum. 2012; 64: 4012-20.
68. Dupont WD., Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990; 11: 116-28.